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ABSTRACT
MicroRNAs (miRNAs) regulate key biological processes, and their aberrant 
expression has been related to cancer development. Photodynamic therapy (PDT) has 
emerged as one of the most promising modalities for cancer treatment. However, the 
application of PDT has been limited to superficially localized human cancerous and 
precancerous lesions. To increase the usefulness of both PDT and miRNAs in cancer 
therapy, this study investigated whether apoptosis-related miRNA expression is 
influenced by PDT in oral cancer and whether miRNAs can enhance PDT efficacy. To 
achieve this goal, we performed a miRNA array-based comparison of apoptosis-related 
miRNA expression patterns following PDT using pheophorbide a (Pa) as a photosensitizer. 
After Pa-PDT, 13.1% of the miRNAs were down-regulated, and 16.7% of the miRNAs 
were up-regulated. Representative miRNAs were selected according to expression 
difference: miR-9-5p, miR-32-5p, miR-143-3p, miR-145-5p, miR-192-5p, miR-193a-5p, 
miR-204-5p, miR-212-3p, miR-338-3p, and miR-451a. Among them, only miR-145-5p 
showed the consistent reduction repeatedly in all cell lines after Pa-PDT. Further, the 
combined treatment of a miR-145-5p mimic and Pa-PDT increased phototoxicity, reactive 
oxygen species generation, and apoptotic cell death, suggesting that miRNAs expression 
could be a useful marker for enhancing the therapeutic effect of Pa-PDT. This study will 
provide a promising strategy for introducing miRNA as cancer therapy.
INTRODUCTION
MicroRNAs (miRNAs, miRs) are a class of highly-
conserved, short, non-coding RNAs that have emerged as 
important mediators of translational control. By causing 
translational arrest, mRNA cleavage or a combination of the 
two, miRNAs regulate the expression of their target genes, 
mostly via direct targeting of the 3’-untranslated region 
(UTR) of mRNAs [1–3]. Additionally, miRNAs regulate 
a wide range of biological processes, including apoptosis, 
differentiation and cell proliferation [4, 5]. Aberrant expression 
and function of miRNAs have been reported in many types 
of cancers [6, 7]. The pattern of miRNA expression varies 
dramatically across tumor types, and miRNA profiles reflect 
the developmental lineage and differentiation state of a tumor 
[8]. Moreover, miRNAs might enhance chemosensitivity and 
radiosensitivity in human cancer therapy [9, 10].
Photodynamic therapy (PDT) has received 
considerable attention as an alternative treatment modality 
in human cancer [11]. In particular, it is widely accepted 
that PDT has therapeutic effects on melanoma, leukemia, 
hepatocellular carcinoma, and oral squamous cell carcinoma 
(OSCC) [12–15]. The merits of PDT include selective 
treatment of disease sites, simple surgical procedure, and 
minimal damage. PDT includes two individually non-toxic 
components: light and a photosensitizer. Photosensitizers are 
taken up by tumor cells and are subsequently activated by 
light, producing reactive oxygen species (ROS) and causing 
cell death [16]. However, PDT has only shown limited 
success because of unanticipated side effects and insufficient 
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tumor selectivity. Because of these shortcomings, clinical 
adoption of PDT has been partially successful only on 
superficially located cancers such as skin cancer or OSCC.
Considering that miRNAs facilitate chemosensitivity 
and radiosensitivity in cancer treatment, this study attempted 
to investigate whether miRNA expression is influenced by 
PDT and whether miRNAs can enhance the therapeutic effect 
of PDT. To achieve this goal, apoptosis-related miRNAs were 
analyzed in oral cancer after PDT using pheophorbide a (Pa) 
as a photosensitizer. We found that miRNA expression was 
altered by Pa-PDT. In particular, expression of miR-145-5p, 
an apoptosis-related miRNA, was markedly reduced, and 
treatment with a miR-145-5p mimic enhanced phototoxicity. 
This study demonstrates the feasibility of this novel approach 
introducing miRNA expression as a marker for enhancing the 
efficacy of PDT in cancer therapy.
RESULTS
Profiling of apoptosis-related miRNA expression 
by Pa-PDT
To investigate whether miRNA expression is 
influenced by Pa-PDT, 84 apoptosis-related miRNAs 
were profiled in YD1OB OSCC cells using human 
microRNA arrays and quantitative PCR analysis. After 
treatment with Pa-PDT, 13.1% of the miRNAs were 
down-regulated, while 16.7% of the miRNAs were 
up-regulated compared to untreated cells (Figure 1A). 
We found that miR-145-5p was predominantly down-
regulated (Figure 1B). To confirm these data, we 
selected 4 miRNAs showing the greatest up-regulation 
and down-regulation and repeated quantitative real-time 
PCR with 3 OSCC cell lines. Only miRNA-145-5p was 
consistently down-regulated by Pa-PDT in all cell lines 
(Figure 1C).
Cytotoxicity and ROS generation by miR-145-5p 
expression
To determine whether miR-145-5p has a major 
role in the efficacy of PDT, 2 types of IHOK cell 
lines and 7 oral cancer cell lines were screened for 
endogenous expression of miR-145-5p (Figure 2A). 
Regarding that each pair of IHOK cell lines and YD15 
and YD15M (a metastatic cell line of YD15) cell lines 
Figure 1: Apoptosis-related miRNAs expression profiling by Pa-PDT (A) Cells were incubated with 0.3 μM Pa for 2 h in 
a dark room. Cells were then rinsed with PBS and irradiated by light (0.5 J/cm2). Hierarchical clustering of miRNA expression obtained 
with miScript miRNA microarrays and a Venn diagram of miRNA expression depicted the down-regulation and up-regulation of miRNAs 
by Pa-PDT. (B) Representative (top five) down-regulated and up-regulated miRNAs in YD10B. (C) Change in expression of representative 
miRNAs down-regulated and up-regulated by Pa-PDT in several cell lines was confirmed using quantitative real-time PCR.
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showed a difference in expression of miR-145-5p, 
we selected them and examined their cell viabilities. 
The cell lines (IHOK(S) and YD15) showing higher 
endogenous expression of miR-145-5p revealed higher 
sensitivity to Pa-PDT than each paired cell line showing 
lower expression (Figure 2B). Upon treating a miR-
145-5p mimic, cell viabilities of all 4 cell lines were 
significantly reduced (Figure 2C). ROS generation 
increased in all 4 cell lines after treating a miR-145-5p 
mimic. However, only IHOK(S) and YD15 cells, which 
showed higher miR-145-5p expression, had statistically 
significant differences in ROS generation (Figure 2D). 
These data suggested that the higher expression of 
miR-145-5p exerts the more potent PDT effect. Before 
PDT, the cell viability by transfection of a miR-145-
5p mimic showed no difference in all 4 cell lines 
(data not shown).
Induction of apoptosis by combined treatment of 
miR-145-5p mimic and PDT
To investigate whether the combined treatment 
of miR-145-5p mimic and Pa-PDT enhances apoptosis 
of cancer cells, we carried out annexin V/PI staining in 
IHOK(S) and YD15 cells. Compared to the treatment with 
miR-CONT, the number of apoptotic cells increased in 
both IHOK(S) and YD15 cells after combined treatment 
with the miR-145-5p mimic and Pa-PDT (Figure 3A and 
3B).Apoptosis-related proteins, e.g., cleaved forms of 
caspase-9 and caspase-3, increased after treatment with the 
miR-145-5p mimic (Figure 3C), confirming that the high 
expression of miR-145-5p promotes apoptotic cell death 
in cancer cells by Pa-PDT. However, cleaved forms of 
caspase-9 showed no difference in YD15M after treatment 
with the miR-145-5p mimic (data not shown).
Figure 2: Cytotoxicity and ROS generation by miR-145-5p expression (A) Endogenous expression levels of miR-145-5p in IHOK and 
OSCC cells using real-time PCR. (B) Efficacy of Pa-PDT as a function of endogenous miR-145-5p expression. Cell viability was measured 
via MTT assay. (C) Cells were transfected with the miR-CONT or miR-145-5p mimic and then treated with PDT (0.3 μM, 0.5 J/cm2). Cell 
viability was measured via MTT assay. (D) After transfection with the miR-CONT or miR-145-5p mimic and incubation with 0.3 μM Pa 
for 2 h in a dark room, cells were gently rinsed with PBS and incubated with 10 μM of ROS dye at 37 °C and 5% CO2 for 20 min. After 
rinsing with PBS, cells were irradiated by light (0.5 J/cm2). After a 15 min incubation, the amount of ROS generated was quantified using 
flow cytometry. Data represent the median and 95% confidence interval of three independent samples, and the experiment was repeated 
three times per sample. Asterisks indicate statistical significance (* p<0.05).
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RUNX3 activation by targeting of miR-145-5p
Our previous study found that RUNX3 expression 
was proportional to Pa-PDT effect in OSCC cell lines, 
suggesting that RUNX3 might be a sensitive biomarker to 
determine the effect of Pa-PDT [17]. To validate whether 
miR-145-5p modulates RUNX3 expression, three miRNA 
target prediction algorithms (TargetScan, miRanda, and 
PicTar ) were applied and putative binding sites for miR-145-
5p were revealed in the RUNX3-3’UTR (Figure 4B). IHOK 
and OSCC cells were screened to examine endogenous 
expression of RUNX3 (Figure 4A). Corresponding to miR-
145-5p expression, IHOK(S) and YD15 cells showed the 
highest expression level of RUNX3. To evaluate whether 
miR-145-5p activates RUNX3 expression, miR-145-
5p mimic or inhibitor was transfected into IHOK(S) and 
YD15. The miR-145-5p mimic induced mRNA and protein 
expression of RUNX3 whereas miR-145-5p inhibitor 
suppressed mRNA and protein expression of RUNX3 in 
IHOK(S) and YD15 (Figure 4C and 4D). Before PDT, the 
cell viability by transfection of a miR-145-5p mimic or 
inhibitors showed no difference (data not shown).
Proapoptotic bim upregulation by Pa-PDT
To investigate the downstream pathway causing 
apoptosis in miR-145-5p-RUNX3 axis, the expression 
of several apoptosis-related proteins was examined. Like 
miR-145-5p, RUNX3 expression was reduced by Pa-PDT. 
In contrast, Bim expression increased by Pa-PDT, whereas 
the expression of Bax and Bcl-2 showed no difference 
(Figure 5A and 5B).
Figure 3: Apoptosis induction by combined treatment of miR-145-5p mimic and PDT (A) Cells were transfected with the miR-CONT 
or miR-145-5p mimic and then treated with Pa-PDT (0.3 μM, 0.5 J/cm2). After 4 h, cells were collected and double stained with annexin 
V/PI and analyzed using flow cytometry. (B) Cells were transfected with the miR-CONT or miR-145-5p mimic and then treated with 
Pa-PDT (0.3 μM, 0.5 J/cm2). Quantitative analysis indicated the population of apoptotic cells. Data represent the median and 95% confidence 
interval of three independent samples, and the experiment was repeated three times per sample. Asterisks indicate statistical significance 
(* p<0.05). (C) After 4 h, proteins were extracted from cells and resolved using 10% SDS-PAGE. Apoptosis-related proteins were detected 
using western blotting. Cropped gels retain suitable bands for each of antibodies. The relative intensity of protein expression was measured 
by Image J software.
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Figure 4: RUNX3 regulation by targeting of miR-145-5p (A) Endogenous protein levels of RUNX3 in IHOK and 
OSCC cells. (B) Bioinformatics tools were used to predict the binding region of miR-145-5p in the RUNX3-3’UTR. (C-D) RUNX3 
expression was positively regulated to transfection of miR-145-5p mimic(C) or inhibitor(D) in IHOK(S) and YD15. Data represent the 
mean±SD of three independent samples, and the experiment was repeated three times per sample (* p<0.05). Cropped gels retain suitable 
bands for each of antibodies. The relative intensity of protein expression was measured by Image J software.
Figure 5: The expression of apoptosis-related genes through RUNX3 downstream by Pa-PDT. (A-B) Cells were treated 
with Pa-PDT (0.3 μM Pa and 0.5 J/cm2). After 4 h, the cells were collected and the protein expression of RUNX3, Bax, Bim, and Bcl-2 
were measured by western blotting. Cropped gels retain suitable bands for each of primers and antibodies. The relative intensity of protein 
expression was measured by Image J software.
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DISCUSSION
PDT has been considered an effective treatment 
modality in many tumor types, and its effectiveness as 
a curative and palliative therapy is well documented, 
especially in the context of skin cancer. Numerous 
ongoing clinical studies have been designed to optimize 
PDT conditions. However, no standardized biological 
markers of cell death and PDT efficacy other than cell 
viability have been reported. Therefore, this study aimed 
to investigate whether apoptosis-related miRNA levels 
have an effect on PDT in OSCC.
We first examined whether miRNA expression was 
altered after Pa-PDT. With miRNA array-based expression 
analysis, several miRNAs were significantly down-
regulated: the five miRNAs with the largest decreases 
were miR-32-5p, miR-143-3p, miR-145-5p, miR-338-3p, 
and miR-451a. Other miRNAs were up-regulated: the 
five miRNAs with the largest increases were miR-9-5p, 
miR-192-5p, miR-193a-5p, miR-204-5p, and miR-212-
3p. The alteration of miRNA expression by PDT did not 
seem to be specific to Pa-PDT, as evidenced by Figure 
1C. Only miR-145-5p was consistently down-regulated 
after Pa-PDT, lending support that miR-145-5p can be a 
target molecule to enhance PDT efficacy. The miR-145 
has been acknowledged to be a tumor suppressor. The 
miR-145 is able to suppress cancer proliferation, invasion 
and metastases through suppression of mucin-1[18], 
RTKN[19], c-Myc[20], and EGFR[21].
To evaluate whether miR-145-5p enhances PDT 
efficacy in oral cancer, we selected two pairs of cell 
lines (IHOK(S) and IHOK(P), YD15 and YD15M), for 
each pair harbors less genetic variation than among cell 
lines from heterogenous origin. In our results, each pair 
of cell lines showed a difference in expression of miR-
145-5p. We found that enhanced photosensitivity and 
ROS generation corresponded to increased expression of 
apoptosis-related miR-145-5p. In addition, the combined 
treatment of a miR-145-5p mimic and Pa-PDT elicited 
higher phototoxicity than the simple treatment of Pa-PDT. 
We also found that Pa-based PDT followed by transfection 
of a miR-145-5p mimic could significantly increase the 
induction of apoptosis. Ultimately, controlling miR-145-
5p expression or activity could contribute to enhanced 
sensitivity of PDT in oral cancer.
To understand the mechanism why miR-145-5p 
expression enhances PDT efficacy in oral cancer cells, we 
attempted to see whether miR-145-5p can bind to RUNX3, 
which was found to be a biomarker to determine the 
sensitivity of PDT effect in OSCC in our previous study 
[17]. To investigate the mechanism of miR-145-5p in Pa-
PDT efficacy, we used bioinformatics algorisms and found 
that RUNX3 mRNA 3’-UTR conserved eight- or seven-
base oligonucleotide sites that match the miR-145-5p seed 
region. MicroRNAs have primarily been demonstrated to 
mediate posttranscriptional downregulation of expression, 
translation repression, and deadenylation-dependent decay 
of messages through partially complementary miRNA 
target sites in mRNA UTR. However, miRNAs and their 
associated protein complexes can additionally function to 
posttranscriptionally stimulate gene expression by direct 
and indirect mechanisms [22, 23]. In our study, to validate 
whether RUNX3 expression is regulated by targeting 
of miR-145-5p, miR-145-5p mimic or inhibitor was 
transfected. The miR-145-5p mimic transfection induced 
mRNA and protein expression of RUNX3, whereas the 
miR-145-5p inhibitor transfection reduced RUNX3 
expression, suggesting that miR-145-5p positively 
activates RUNX3 expression. Taken together, the miR-
145-5p expression enhances PDT efficacy via activating 
RUNX3 expression.
Accumulating evidences indicate that gene 
expression is regulated in a context-dependent, cell-
type-specific manner. Corroborating this view, RUNX3 
acts as tumor suppressor in gastro-intestinal cancers 
[24] and acts as an oncogene in head and neck cancer 
[25]. Likewise, widespread context dependency of 
miRNA-mediated regulation has been investigated, 
implying a much more complex post-transcriptional 
regulatory network than is currently known [26]. Given 
our results that the expression of miR-145-5p and 
RUNX3 was reduced by PDT, we could extrapolate that 
miR-145-5p and RUNX3 may also act as oncogene in 
oral cancer. In gastric cancer, RUNX3 cooperates with 
FoxO3a to participate in the induction of apoptosis 
by activating Bim [27]. Our data showed that Bim 
expression increased with reduced expression of miR-
145 and RUNX3 by PDT. Considering that RUNX3 
may cooperate with known or unknown cofactors 
maintaining its functional balance, Pa-PDT may break 
the functional balance of RUNX3 interacting with 
cofactors, inducing Bim expression, subsequently 
eventuating in apoptosis. However, considering context 
dependency of miRNA function, whether miR-145 may 
interact with other target sites by PDT should be further 
illuminated. Given the data that apoptotic cell death 
showed no difference in YD15M after treatment with 
the miR-145-5p mimic (data not shown), we extrapolate 
that the metastatic cell lines may interact with different 
target molecules from its original cell lines, eventuating 
in different outcome.
Taken together, the expression levels of apoptosis-
related miRNAs were altered following Pa-PDT. The 
overexpression of miR-145-5p strengthens PDT efficacy. 
PDT has been limitedly applied to superficially located 
cancer, because of its potency and insufficient selectivity. 
To maximize the beneficial effects of PDT, the expression 
level of miR-145-5p can be a useful biomarker to 
predetermine patients’ sensitivity to PDT. Further, this 
study provides an insight to enhance the efficacy of Pa-
PDT and serves as a new therapeutic strategy for effective 
treatment of oral cancer.
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MATERIALS AND METHODS
Cell culture
We used 7 oral cancer cell lines (YD9, YD10B, 
YD32 and YD38 are OSCC cell lines; YD15 is a 
mucoepidermoid carcinoma cell line and YD15M is a 
metastatic cell line of YD15) [28] and 2 immortalized 
human oral keratinocyte (IHOK) cell lines for this study 
[17, 29]. IHOK cell lines were obtained by transfection 
of human papilloma virus (HPV) 16 E6/E7 DNA [29]. 
Two subtypes were obtained from the parent IHOK cell 
line based on morphology: IHOK(S) for spindle shape 
and IHOK(P) for polygonal shape [17]. Authentication 
of all cell lines was verified and shown to be free of 
contamination from other cell lines by Korean Cell Line 
Bank (KCLB). Cells were cultured in DMEM (Gibco 
BRL, USA) and Ham’s-F12 medium (Gibco BRL, USA) 
mixed in a 3:1 ratio and supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin, 0.01 
μg/ml cholera toxin, 0.04 μg/ml hydrocortisone, 0.5 μg/
ml insulin, 0.5 μg/ml apo-transferrin, and 0.2 μg/ml 
3’-5-triodo-1-thyroxine (Sigma, MO, USA). Cells were 
grown at 37 °C in a humidified incubator with 5% CO2.
Photodynamic treatment
The Pa photosensitizer was obtained from Sigma 
(Sigma, MO, USA) and administered at 0.3 μM for 2 h. 
The irradiation dose was 0.5 J/cm2 [17].
Cell viability
Cell viability was assessed using 3-(4, 5-dime-
thylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) 
assay. Briefly, cells were seeded in a six-well plate (2x105 
cells/well), and MTT enzyme activities were measured. MTT 
solution (700 μl; Sigma, MO, USA) was added to each well, 
and cells were incubated for 3 h at 37 °C. After removing 
the MTT solution, 1 ml of DMSO (Sigma, MO, USA) was 
subsequently added to each well to dissolve the formazan 
dye. The optical density was measured at 540 nm with a 
micro-plate reader (Bio-Rad, CA, USA).
miRNA micro-array
miRNA expression was profiled in YD10B (OSCC 
cell line), using miScript miRNA PCR Array (Qiagen, 
Hilden, Germany) in three independent experiments. Real-
time quantitative PCR was performed with a LightCycler 
480 II instrument and the manufacturer’s software (Roche 
Applied Science, Mannheim, Germany). Gene Expression 
Suite software (Qiagen, Hilden, Germany) was used to 
process the array data. Automatic thresholds were checked 
individually and corrected when necessary.
ROS generation
Intracellular levels of ROS were measured using 
the fluorescent probe 2’7’-dichlorofluorescein diacetate 
(H2DCFDA) (Molecular Probes, Inc., OR, USA) 
according to the manufacturer’s instructions. Briefly, cells 
were treated with 0.3 μM Pa for 2 h in a dark room. Cells 
were gently rinsed with PBS and incubated with 10 µM of 
ROS dye at 37 °C for 20 min in the dark. Then, cells were 
gently rinsed with PBS and irradiated by light (0.5 J/cm2). 
Serum-free medium served as a negative control, and 10 
μM H2O2 served as a positive control. After incubating 
for 15 min, ROS generation was measured using flow 
cytometry (Becton Dickinson, CA, USA), and Cell-Quest 
software (BD Biosciences, CA, USA) was used for data 
analysis.
Apoptosis detection
Cells were treated with PDT (0.3 μM Pa and 
0.5 J/cm2 light). After incubating for 4 h, cells were 
resuspended in binding buffer (Annexin V-FITC 
Apoptosis Detection Kit; BD Bioscience, CA, USA) at 
a concentration of 1x106 cells/ml. Next, 4 µl of FITC 
annexin V and 4 µl of propidium iodide were added 
to 100 µl of cell suspension. After incubating in the 
dark for 15 min, 400 µl of binding buffer was added. 
Apoptosis was analyzed using flow cytometry (Becton 
Dickinson, CA, USA) using BD Cell-Quest software 
(BD Biosciences, CA, USA).
Immunoblotting
Cells were treated with PDT, incubated for 4 
h, then lysed (1.5x105 cells) in cell lysis buffer (Cell 
Signaling Technology, MA, USA). Next, proteins were 
separated using 10% SDS-PAGE and transferred to a 
methanol-activated polyvinylidene fluoride membrane 
(Bio-Rad, CA, USA). The membrane was blocked for 
1 h in PBST containing 5% milk and subsequently 
probed with anti-cleaved caspase-3 antibody, anti-
cleaved caspase-9 antibody (Cell Signaling Technology, 
MA, USA), anti-RUNX3 (1:1,000) was obtained 
from Abcam (Abcam, Cambridge, UK). Additionally, 
antibodies against Bax (1:1,000), Bim (1:1,000) and Bcl-
2 (1:1,000) were obtained from BioVision (BioVision, 
CA, USA). An anti-actin antibody (1:2,000) was used as 
a loading control (Sigma, MO, USA). Blots were then 
incubated for 1 h with horseradish peroxidase-conjugated 
anti-mouse (1:2,000) or rabbit (1:2,000) secondary 
antibodies (Cell Signaling Technology, MA, USA), and 
detection was done by chemiluminescence (Santa Cruz 
Biotechnology, CA, USA). The density was detected 
using chemiluminescence (Santa Cruz Biotechnology, 
CA, USA).
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Real-time PCR
Total RNA was extracted from whole cells and 
nucleoli using TRIzol Reagent and the RNeasy Kit 
(Qiagen, Hilden, Germany). To avoid DNA contamination, 
all samples were subjected to DNase treatment. In brief, 
100 ng of purified total RNA were reverse transcribed, 
and quantification of specific miRNAs and U6 control 
transcripts was accomplished using the miScript SYBR 
Green PCR Kit (Qiagen, Hilden, Germany) with miScript 
Primer Assays HS-miR-9-5p (#MS00010752), Hs-miR-
145-5p (#MS00003528), Hs-miR-192-5p (#MS00003689) 
and Hs-miR-338-3p (#MS00003990) according to the 
manufacturer’s instructions. Amplification and detection 
of specific products were performed using a LightCycler 
480 II instrument (Roche Applied Science, Mannheim, 
Germany) at 95 °C for 15 min, followed by 45 cycles of 
94 °C for 15 s, 55 °C for 30 s, and 70 °C for 30 s. The 
threshold cycle (Ct) of each target gene was automatically 
defined, located in the liner amplification phase, and 
normalized against expression of the U6 control.
Reverse transcriptase (RT)-PCR
Total RNA was isolated from each cell lysate using 
an RNeasy kit (Qiagen, Hilden, Germany), and cDNA 
was synthesized from 1 μg of the total RNA by using an 
Accu Power Hot Start PCR Pre Mix (Bioneer, Daejeon, 
South Korea) according to the manufacturers’ protocols. 
The following primers were used for RUNX3; forward 
(F): 5’-GGTACGGTGGTGACTGTGAT-3’, reverse 
(R): 5’-TGAACACACAGTGATGGTCAGG-3’, Bax; 
F: 5’-CCTTTTCTACTTTGTCAGCAA-3’, R: 5’-GAG 
GCCGTCCCAACCAC-3’, Bcl-2; F: 5’-GCCCTG 
TGGATGACTGAGTA-3’, R: 5’-ACTTGTGGCTCA 
GATAGGCA-3’, Bim; F: 5’-ATGGCAAAGCA 
ACCTTCT-3’, R: 5’-CGCATATCTGCAGGTTCA 
GCC-3’, GAPDH; F: 5’-GAAGGTGAAGGTCGGA 
GT-3’, R: 5’-GAAGATGGTGATGGGATTTC-3’. The 
reaction mixture was subjected to 30 cycles of 30 s at 94 °C, 
30 s at 61 °C, and 45 s at 72 °C. The PCR products were 
visualized using ethidium bromide in 1% agarose-gel.
miRNA transfection
Transfection of miRNA mimics is used to identify 
the targets and roles of particular miRNAs. In this protocol, 
cell seeding and transfection were performed on the same 
day. Shortly before transfection, cells (1.5x105) were 
seeded in a 35-mm dish in 800 μl of an appropriate culture 
medium containing serum and antibiotics. The miR-145-
5p mimic (#MSY0000437) and the miR-145-5p inhibitor 
(#MIN0000437) (Qiagen, Hilden, Germany) were diluted to 
a final concentration of 20 nM in 200 μl of culture medium 
without serum. Next, 3 μl of HiPerFect Transfection Reagent 
(Qiagen, Hilden, Germany) were mixed with the diluted 
mimic and inhibitor by vortexing. The samples were then 
incubated for 10 min at room temperature to allow forming 
transfection complexes. Subsequently, the complexes were 
added drop-wise to the cells. The transfected cells were 
cultured for 48 h before assay. The miRNA-control (miR-
CONT) (#1027271) (Qiagen, Hilden, Germany) was used.
Bioinformatics
Candidate RUNX3 targets were generated using the 
publicly available algorithms TargetScan (http://www.
targetscan.org), miRanda (http://www.microrna.org), and 
PicTar (http://www. pictar.mdc-berline.de). For searching 
the binding region of miR-145-5p in the RUNX3-3’UTR, 
the “conserved” predictions were used in TargetScan.
Statistical analysis
To determine statistically significant differences 
between measurements, Mann-Whitney U tests 
were performed. P values of <0.05 were considered 
significant. Unless otherwise stated, data presented were 
representative of three independent experiments.
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